Prostate Cancer is the second most common malignancy in men worldwide, after lung cancer. Most Prostate Cancers grow slowly and remain confined to the prostate gland while some develop a more aggressive form and metastasize to other body parts that can be potentially lethal.
Currently, the Prostate Cancer domain constitutes an immensely robust pipeline with more than 200 drugs under different phases of development. Even along with the presence of so many therapeutic drugs, Prostate Cancer remains the second most common cause of cancer death in American men and its incidence has doubled over the past two decades.
DelveInsight presents a new addition to its newsletter edition that focuses on the Prostate Cancer market. The newsletter offers a complete picture of the Prostate Cancer market landscape, ongoing clinical trials, pipeline therapies that are expected to transform the Prostate Cancer market in the coming decade. Gain rich insights into Prostate Cancer epidemiological insights, current treatment therapies, details of the latest news and happenings, mergers and collaborations, critical pharmaceuticals involved, licensing deals along with events and top-level conferences taking place in the Prostate Cancer field
Interested in knowing more about what upcoming years hold for the Prostate Cancer market and how pharma companies are working to push the drug development? Download our Newsletter by simply filling up the form towards the right.
Subscribe to our mailing list and stay informed about all the recent breakthroughs in the Oncology market.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- R&D in the field
- Top conferences
- News flash
- Recent Research Activities
- Support from International organizations
- Market insights
- Prostate Cancer Market Dynamics
- Collaborations and deals in the domain